Aadi Bioscience (FRA:3350) Change In Receivables : €0.55 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Aadi Bioscience Change In Receivables?

Aadi Bioscience's change in receivables for the quarter that ended in Mar. 2024 was €0.51 Mil. It means Aadi Bioscience's Accounts Receivable declined by €0.51 Mil from Dec. 2023 to Mar. 2024 .

Aadi Bioscience's change in receivables for the fiscal year that ended in Dec. 2023 was €-3.33 Mil. It means Aadi Bioscience's Accounts Receivable increased by €3.33 Mil from Dec. 2022 to Dec. 2023 .

Aadi Bioscience's Accounts Receivable for the quarter that ended in Mar. 2024 was €4.54 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Aadi Bioscience's Days Sales Outstanding for the three months ended in Mar. 2024 was 84.08.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Aadi Bioscience's liquidation value for the three months ended in Mar. 2024 was €68.38 Mil.

Aadi Bioscience Change In Receivables Historical Data

The historical data trend for Aadi Bioscience's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aadi Bioscience Change In Receivables Chart

Aadi Bioscience Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Change In Receivables

-11.40

12.52

-1.76

-3.33

Aadi Bioscience Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial										-3.46	1.74	-1.91	0.21	0.51

Aadi Bioscience Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.55 Mil.

Aadi Bioscience (FRA:3350) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Aadi Bioscience's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	4.538	/	4.925	*	91
=	84.08

2. In Ben Graham's calculation of liquidation value, Aadi Bioscience's accounts receivable are only considered to be worth 75% of book value:

Aadi Bioscience's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	81.209	-	18.964	+	0.75 * 4.538	+	0.5 * 5.461
=	68.38

Aadi Bioscience Change In Receivables Related Terms

Thank you for viewing the detailed overview of Aadi Bioscience's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Aadi Bioscience (FRA:3350) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aadi Bioscience Inc (FRA:3350) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

AADI:USA 3350:Germany

Address

17383 Sunset Boulevard, Suite A250, Pacific Palisades, CA, USA, 90272

Website

https://www.aadibio.com

Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.

Aadi Bioscience (FRA:3350) Headlines

No Headlines